Evaluation of Exenatide in Patients With Diabetic Neuropathy

Completed 46 enrolled University of Michigan Amylin Pharmaceuticals, LLC. · collab Eli Lilly and Company · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.

Timeline

Start: 2008-06
Primary completion: 2014-05
Completion: 2014-05

Outcome

Missed primary endpoint

paper There were no statistically significant treatment group differences in the prevalence of CCN PMID 26264399 ↗

Publications

Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL, Pop-Busui R. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications. 2015 Nov-Dec;29(8):1287-94. doi: 10.1016/j.jdiacomp.2015.07.013. Epub 2015 Jul 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	—	Subcutaneous
Comparator	insulin glargine	Protein / enzyme biologic	—	—